Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)

Marcelo Maia Pinheiro*,1, Andrea Fabbri2 & Marco Infante**,2,3,4
1Faculty of Medicine, UNIVAG University Center, Várzea Grande, Mato Grosso, Brazil
2Department of Systems Medicine, Division of Endocrinology & Diabetes, Diabetes Research Institute Federation (DRIF), CTO Hospital, University of Rome Tor Vergata, Rome, Italy
3UniCamillus, Saint Camillus International University of Health Sciences, Section of Endocrinology, Diabetes and Metabolism, Rome, Italy
4Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Rome, Italy
*Author for correspondence: marcelo.pinheiro@univag.edu.br
**Author for correspondence: marco.infante@unicamillus.org

A dysregulated immune response characterized by the hyperproduction of several pro-inflammatory cytokines (a.k.a. ‘cytokine storm’) plays a central role in the pathophysiology of severe coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this Perspective article we discuss the evidence for synergistic anti-inflammatory and immunomodulatory properties exerted by vitamin D and dipeptidyl peptidase-4 (DPP-4) inhibitors, the latter being a class of antihyperglycemic agents used for the treatment of Type 2 diabetes, which have also been reported as immunomodulators. Then, we provide the rationale for investigation of vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) as an immunomodulation strategy to ratchet down the virulence of SARS-CoV-2, prevent disease progression and modulate the cytokine storm in COVID-19.

Lay abstract: The so-called ‘cytokine storm’ that drives the hyperproduction of pro-inflammatory mediators, plays a central role in the pathophysiology of severe coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vitamin D has increasingly been shown to play anti-inflammatory and immunomodulatory properties beyond its role in the regulation of bone homeostasis. Similarly, dipeptidyl peptidase-4 inhibitors (DPP-4i) – a class of antihyperglycemic agents used for the treatment of Type 2 diabetes – have been reported as immunomodulators regardless of their glucose-lowering properties. We, therefore, discuss the role of vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) as a potential immunomodulation strategy to prevent the development and/or halt the progression of the COVID-19-induced cytokine storm, particularly in patients with diabetes and cardiovascular disease.

Tweetable abstract: Vitamin D and DPP-4 inhibitors exert anti-inflammatory and immunomodulatory properties. Vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) may represent a valid therapeutic approach to ratchet down the virulence of SARS-CoV-2 and modulate the cytokine storm in COVID-19.

First draft submitted: 29 December 2020; Accepted for publication: 13 April 2021; Published online: 28 April 2021

Keywords: cardiovascular disease • COVID-19 • cytokine storm • DPP-4 inhibitors • drug repurposing • immunomodulation • SARS-CoV-2 • Type 2 diabetes • VIDPP-4i • vitamin D

Since the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic on March 2020, there has been an unprecedented public health crisis which has placed an enormous strain on healthcare systems worldwide. Older age, cardiovascular disease (CVD),
diabetes, obesity, malignancy, chronic lung disease, chronic kidney disease and chronic liver disease have emerged as independent risk factors for adverse clinical outcomes and mortality related to COVID-19 [1–3].

A dysregulated immune response called a ‘cytokine storm’ (also known as ‘cytokine-release syndrome’) and characterized by an excessive increase in circulating levels of several pro-inflammatory cytokines (such as IL-1, IL-2, IL-6, IFN-γ and TNF) has been shown to play a central role in the pathophysiology of the most severe cases of COVID-19, leading to acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation, multiorgan failure and ultimately death [4,5]. A marked activation and exhaustion of CD4+ and CD8+ T cells accompanied by a skewing of T-cell activation toward T-helper (Th) 17 functional phenotype have been reported in patients with COVID-19 and may contribute to the excessive production of effector pro-inflammatory cytokines such as IL-2, TNF and IFN-γ [4,6]. Patients with severe COVID-19 have higher serum concentration of IL-6, IL-10, IL-2 and IFN-γ, higher numbers of neutrophils in the peripheral blood and reduced counts of T cells (particularly CD8+ T cells) compared with patients with mild disease [7]. This suggests that the numbers of neutrophils and T cells, as well as the circulating levels of pro-inflammatory cytokines in the peripheral blood are dynamically correlated with the severity of COVID-19. It is possible that the peripheral lymphopenia – observed especially in patients with severe COVID-19 – reflects the overactivation and functional exhaustion of T cells, as well as the recruitment of lymphocytes to the respiratory tract or adhesion to inflamed respiratory vascular endothelium [8]. Moreover, increased B-cell activation and proliferation have also been correlated with adverse outcomes in severe cases of COVID-19 [9]. Emerging evidence also suggests that endothelial activation and dysfunction contribute to COVID-19 pathogenesis by altering the integrity of vessel barrier, driving a procoagulant state, triggering endothelial inflammation and mediating leukocyte infiltration [10,11].

Diverse SARS-CoV-2 vaccine types are becoming available in different countries and several repurposed drugs have been used for the treatment of COVID-19 since the beginning of the pandemic [12]. Nevertheless, only a few repurposed drugs have been shown to offer a certain degree of effectiveness in preliminary intervention trials [13]. In this Perspective article we propose vitamin D and dipeptidyl peptidase-4 (DPP-4) inhibitors as potential candidates for prevention and modulation of cytokine storm in patients with COVID-19 based on the most recent evidence. DPP-4 inhibitors (DPP-4i) represent a class of oral antihyperglycemic agents used for the treatment of Type 2 diabetes (T2D) [14], which have also been reported to play anti-inflammatory and immunomodulatory properties [15]. References for this manuscript were identified through searches of PubMed using the following terms: ‘vitamin D’, ‘cholecalciferol’, ‘calcifediol’, ‘calcidiol’, ‘dipeptidyl peptidase-4’, ‘DPP-4’ and ‘DPP-4 inhibitors’ in combination with ‘COVID-19’, ‘ACE2’, ‘SARS-CoV-2’, ‘cytokine storm’ and ‘cytokine-release syndrome’. With regard to the literature pertaining to COVID-19, no criteria for publication data were set and we included articles published in English between 1 January 2020 and 28 March 2021. We also checked reference lists in relevant articles and Google Scholar for additional references. Articles resulting from these searches and relevant references cited in those articles were reviewed. The final reference list was generated on the basis of these searches to the topics covered in this publication.

Vitamin D & COVID-19

Over the last decade, a number of mechanistic studies demonstrated that vitamin D exerts anti-inflammatory and immunomodulatory properties beyond its well-established role in the regulation of bone homeostasis [16,17]. These properties may occur in vivo upon the achievement of adequate serum 25-hydroxyvitamin D (25[OH]D) levels, which amount to approximately 40–60 ng/ml [17]. The aforementioned properties are exerted by the biologically active form of vitamin D, which is also referred to as 1,25-dihydroxyvitamin D3 or calcitriol. It has been shown that vitamin D plays a central role in the regulation of innate and adaptive immune responses, promoting antiviral effector mechanisms, reducing the expression of pro-inflammatory cytokines and inducing tolerogenic responses [16–18]. In particular, calcitriol has been shown to: upregulate the transcription of antimicrobial peptides (such as cathelicidin and defensin β2) in various human cell lines (myeloid cells, monocytes/macrophages, neutrophils and keratinocytes); promote the differentiation of monocytes/macrophages and enhance their chemotactic and phagocytic capacity; inhibit the production of several pro-inflammatory cytokines (e.g., IL-6 and TNF-α) by monocytes and macrophages; decrease macrophage antigen-presentation and T-cell stimulatory ability; elicit the shift of macrophage polarization from the M1 pro-inflammatory phenotype (‘classically activated macrophages’) towards the M2 anti-inflammatory phenotype (‘alternatively activated macrophages’); render the dendritic cells more tolerogenic and reduce their antigen-presentation capacity; upregulate regulatory T cells; and favor the shift of T cells from an ‘effector’ pro-inflammatory phenotype toward a ‘regulatory’ anti-inflammatory phenotype by reducing Th1
and Th17 cell differentiation and promoting Th2 cell differentiation [16,17]. Importantly, vitamin D receptor has been identified in almost all immune cells [17], as well as in human airway epithelial cells [19]. The nearly ubiquitous expression of vitamin D receptor enables vitamin D to exert its pleiotropic actions, including the regulation of local ‘respiratory homeostasis’ by upregulating the expression of antimicrobial peptides and/or by directly affecting the replication of respiratory viruses [19]. Vitamin D deficiency (defined as serum 25-hydroxyvitamin D levels less than 20 ng/ml) is a global health issue afflicting more than one billion children and adults worldwide [20]. Since the beginning of COVID-19 pandemic, vitamin D deficiency has been suggested as an independent risk factor for SARS-CoV-2 infection and hospitalization, development of cytokine storm and poor outcomes related to COVID-19 [21–26]. Moreover, the overlap between risk factors for vitamin D deficiency and severe manifestations of COVID-19 (such as Black or Asian ethnic origin, living at higher latitudes, older age and obesity) [27,28] led researchers to consider vitamin D deficiency and COVID-19 as two related pandemics [29]. In a large US retrospective, observational study involving more than 190,000 patients with SARS-CoV-2 results from all 50 states, vitamin D deficiency has been associated with significantly higher SARS-CoV-2 positivity rates [30]. Interestingly, the decrease in SARS-CoV-2 positivity rate associated with 25(OH)D levels appeared to plateau as values approached 55 ng/ml, suggesting that additional benefits exist when 25(OH)D levels are higher than the cut-off value used to define vitamin D sufficiency for bone health (30 ng/ml) [30].

Several observational studies have showed that hospitalized patients with COVID-19 exhibit a markedly high prevalence of hypovitaminosis D, and that vitamin D deficiency is associated with a more advanced disease radiologic stage, along with a significantly higher risk of noninvasive mechanical ventilation and in-hospital mortality [31–35]. It has also been shown that serum vitamin D levels are significantly lower in severe/critical COVID-19 cases compared with mild-to-moderate cases [35]. We recently showed that a lower vitamin D status upon admission is significantly and independently associated with an increased risk of COVID-19-related in-hospital mortality [36]. A systematic review and meta-analysis of observational studies conducted by Pereira et al. [37] confirmed a positive association between vitamin D deficiency and COVID-19 severity. In this regard, it is worth mentioning that acute illness and systemic inflammatory response can further lower circulating 25(OH)D levels [38,39], thus explaining, at least in part, the high frequency of severe vitamin D deficiency observed in patients with infectious diseases, including COVID-19 complicated by cytokine release syndrome.

Given the abovementioned anti-inflammatory and immunomodulatory properties of vitamin D, vitamin D deficiency may exacerbate COVID-19 severity and mortality by triggering the hyperinflammatory state and the cytokine storm associated with the most severe cases. Indeed, patients with COVID-19 and vitamin D deficiency have been shown to exhibit significantly higher serum level of several inflammatory and coagulation biomarkers such as C-reactive protein, IL-6, TNF-α, ferritin, fibrinogen and D-dimer [34,36,40]. Therefore, there has been a growing interest in the use of vitamin D as an adjuvant anti-inflammatory and immunomodulatory agent aimed to prevent SARS-CoV-2 infection and/or the progression of COVID-19 toward the severe stage of the disease characterized by the development of cytokine release syndrome [21,41]. Pilot intervention studies investigating the therapeutic role of vitamin D supplementation in COVID-19 yielded promising results. In particular, vitamin D administration (at regular and high doses and in different formulations) has been proven safe and effective in accelerating viral clearance, decreasing fibrinogen levels, reducing the severity of the disease as well as the need for intensive care unit treatment among hospitalized patients (middle-aged and older adults) with COVID-19 [42–45].

Angiotensin-converting enzyme 2 (ACE2), the receptor used by SARS-CoV-2 for cellular entry [46], catalyzes the cleavage of angiotensin II (Ang II) (a vasoconstrictor peptide) into angiotensin 1–7 (Ang-[1–7]) (a vasodilator peptide), thus reducing blood pressure. Moreover, Ang-(1–7) induces nitric oxide synthase (NOS) and further antagonizes Ang II activity via its Ang II type 1 receptor (AT1R) [47]. Following ACE2 receptor binding and SARS-CoV-2 entry into host cells, there is a downregulation of ACE2, resulting in excessive accumulation and pro-inflammatory activity of Ang II potentially accompanied by the development of lung injury, pneumonia, ARDS, myocarditis and/or cardiac injury [48,49]. An analysis on gene expression data from cells in bronchoalveolar lavage fluid from COVID-19 patients has also shown an atypical pattern of the renin-angiotensin system (RAS), which is predicted to elevate bradykinin levels in multiple tissues and promote vasodilation, vascular permeability and hypotension [50]. It has also been suggested that certain polymorphisms in coding, noncoding and regulatory sites of the ACE2 gene may contribute to the worse clinical course of COVID-19 observed in males and in different regions worldwide [51]. Thus, ACE2 polymorphisms may partly facilitate or reduce the risk of SARS-CoV-2 infection and adverse outcomes of COVID-19 by affecting the translation regulation and expression of ACE2.
Importantly, vitamin D has been suggested as a negative endocrine modulator of the RAS [47,49]. Of note, vitamin D may decrease the risk of SARS-CoV-2 infection and protect against the symptoms of COVID-19 by inhibiting the synthesis of renin (a proteolytic enzyme and a positive regulator of Ang II) and by increasing ACE2 expression and Ang-(1–7) production in the lung, thus preventing Ang II accumulation, decreasing the pro-inflammatory activity of Ang II and reducing the risk of ARDS, myocarditis and cardiac injury [47,49].

Recently, it has also been suggested that polymorphisms of the vitamin D binding protein (DBP) gene may influence circulating 25(OH)D levels and, as a consequence, COVID-19 pathophysiology (in terms of susceptibility to and mortality from SARS-CoV-2 infection). DBP is a serum α-globulin encoded by the GC gene and represents the major binding/transport protein of all vitamin D metabolites. Under physiological conditions, the majority of vitamin D metabolites (85–90%) are tightly bound to DBP, whereas only 10–15% of the circulating vitamin D is bound to albumin, and less than 1% represents the unbound (free) form of vitamin D. Besides mediating the transport of vitamin D metabolites and regulating the access of such metabolites to cells and tissues, DBP exerts other important functions such as fatty acid transport, actin scavenging, macrophage activation and chemotaxis [52,53]. Notably, a recent study revealed a significant association between the DBP1 allele frequency and a lower COVID-19 prevalence and mortality, suggesting that DBP1 carriers may be less susceptible to SARS-CoV-2 infection and mortality related to COVID-19 [54]. However, further research is needed to better elucidate the relationship between DBP and its polymorphisms, vitamin D and COVID-19 pathophysiology.

**Dipeptidyl peptidase-4 (DPP-4), DPP-4 inhibitors & COVID-19**

Dipeptidyl peptidase-4 (DPP-4, also referred to as cluster of differentiation 26 or CD26) is a serine exopeptidase existing in two forms: a plasma membrane-bound form (mDPP-4, consisting of a type II transmembrane homodimeric glycoprotein) and a soluble form (sDPP-4). The soluble form maintains its enzymatic (peptidase) activity and is thought to be released from the membrane into the circulation. DPP-4/CD26 is expressed ubiquitously in several cells and tissues, including, but not limited to, kidney, lung, endothelia, liver, intestine and immune cells such as T cells, activated B cells, activated natural killer cells and myeloid cells [55]. DPP-4 has previously been identified as a functional receptor for the spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV) mediating the virus entry into host cells [56].

DPP-4 inhibitors (DPP-4i, also known as gliptins) have been widely used since 2006 as oral antihyperglycemic agents for the treatment of T2D and have been proven effective in improving glucose control by preventing the DPP-4-mediated cleavage and inactivation of incretin hormones, enhancing endogenous insulin secretion and suppressing glucagon secretion [14]. DPP-4i include sitagliptin, saxagliptin, alogliptin, linagliptin and vildagliptin. In April 2020, we published an article in CellR4 highlighting the possible therapeutic role of DPP-4 and DPP-4i in COVID-19 pathophysiology [57].

Both SARS-CoV and SARS-CoV-2 use ACE2 as the primary receptor for viral entry into host cells [46]. However, bioinformatics approaches combining human-virus protein interaction prediction, computational model-based selective docking and protein-docking based on crystal structures suggest DPP-4 as a candidate binding target of the receptor-binding S1 domain of the SARS-CoV-2 spike glycoprotein. In addition, the crucial binding residues of DPP-4 are identical to those that are bound to the spike protein of MERS-CoV [58,59]. Since DPP-4 is ubiquitously expressed in several cells and tissues other than lung and respiratory tract, it may therefore participate into the direct SARS-CoV-2-mediated injury of such tissues. Thus, DPP-4 inhibition may have the potential to counteract the DPP-4-mediated SARS-CoV-2 hijacking and virulence and to improve clinical outcomes of COVID-19 by interfering with the interaction between SARS-CoV-2 and target host cells [60-62].

However, the main glucose-independent mechanisms that potentially account for beneficial effects of DPP-4i in COVID-19 include the immunomodulatory, anti-inflammatory and antifibrotic properties exerted by these drugs, which may represent a valid therapeutic tool to prevent or halt the progression toward the hyperinflammatory state and cytokine storm associated with the most severe COVID-19 cases [63-65]. Indeed, a large number of studies demonstrated that DPP-4/CD26 modulates both innate and adaptive immune responses [15,55]. DPP-4/CD26 is expressed only on a fraction of resting T cells, while it becomes significantly upregulated upon T-cell activation [55]. DPP-4/CD26 on T-cell surface induces co-stimulatory effects on T-cell activation, resulting in increased production of Th1 and pro-inflammatory cytokines TNF-α, IFN-γ and IL-6 [66]. CD26-mediated co-stimulation of CD8+ T cells exerts a cytotoxic effect primarily via granzyme B, IFN-γ, TNF-α and Fas ligand [67]. In a study conducted by Bengsch et al. [68], human Th17 cells producing type 17 cytokines (e.g., IL-17, IL-22, TNF) exhibited the highest levels of enzymatically active DPP-4/CD26 compared with Th1, Th2 and regulatory T cells. Of note, the lowest
CD26 expression levels were identified for IL-10-producing CD4+ T cells and CD25hiCD127−FOXP3+ regulatory T cells, suggesting suppressive effects exerted by CD26 on such anti-inflammatory cells [68]. Upon activation, approximately 50% of human B cells express DPP-4/CD26 and targeted suppression of DPP-4 activity decreases B-cell activation and DNA synthesis in a dose-dependent manner [55]. Remarkably, a recent large retrospective cohort study conducted on 774,198 patients with T2D showed that the use of DPP-4i is associated with lower risk of autoimmune disorders [69].

DPP-4 inhibition has been shown to attenuate lipopolysaccharide-induced lung injury in murine models of ARDS and to inhibit the release of TNF-α, IL-6 and IL-8 by human lung microvascular endothelial cells [70]. Soare et al. [64] recently found that pharmacological inhibition of DPP-4 promoted regression of bleomycin-induced dermal thickness in murine models of systemic sclerosis, and DPP4-knockout mice were less susceptible to bleomycin-induced dermal and pulmonary fibrosis.

Of note, two Italian retrospective observational studies recently showed that the use of DPP-4i at the time of hospital admission in patients with T2D and COVID-19 was associated with reduced mortality, improved clinical outcomes, lower need for noninvasive mechanical ventilation and greater number of hospital discharges [71,72]. In the study conducted by Solerte et al. [71], authors included 338 consecutive hospitalized T2D patients with COVID-19 (169 were on standard of care, while 169 were on sitagliptin). Sitagliptin treatment at the time of hospitalization was associated with reduced mortality (hazard ratio: 0.44 [95% CI: 0.29–0.66]; p = 0.0001), along with an improvement in clinical outcomes (60 vs 38% of improved patients; p = 0.0001) and with a higher number of hospital discharges (120 vs 89 of discharged patients; p = 0.0008) compared with patients receiving standard of care, respectively [71]. The study conducted by Mirani et al. [72] was a case series involving 387 hospitalized patients with COVID-19; 90 out of 387 participants (23.3%) had T2D. In diabetic patients, the use of DPP-4i was significantly and independently associated with a lower risk of mortality (adjusted hazard ratio: 0.13; 95% CI: 0.02–0.92; p = 0.042) [72]. A recent systematic review and meta-analysis of observational studies found that in-hospital DPP4i use is associated with a significantly reduced COVID-19 mortality in diabetic patients [73]. These findings suggest that diabetic patients with COVID-19 taking DPP-4i may exhibit less severe COVID-19-related pneumonia and end-organ complications.

Additionally, it has been suggested that DPP-4i may exert cardioprotective effects via various mechanisms involving insulin resistance, dysfunctional immunity, oxidative stress, apoptosis, dyslipidemia, adipose tissue dysfunction, as well as antiapoptotic properties of these drugs in the heart and vasculature [74]. A number of studies (mostly preclinical) have shown that DPP-4i can facilitate wound healing, improve endothelial function and prevent the development and progression of atherosclerosis by reducing neutrophil recruitment and activity, attenuating vascular oxidative stress and modulating monocyte/macrophage-mediated responses [15].

Therefore, Du et al. [75] have recently proposed DPP-4 inhibition as a potential therapeutic strategy aimed to alleviate the cardiovascular injury (including arrhythmia, acute coronary syndrome and heart failure) caused either directly by SARS-CoV-2 or indirectly by the COVID-19-induced cytokine storm. We previously conducted an in vitro study to assess the effects of the DPP-4 inhibitor sitagliptin on human peripheral blood mononuclear cells from healthy volunteers [76]. We demonstrated that sitagliptin is able to markedly reduce the expression of IL-6, IL-17 and IFN-γ and to stimulate the differentiation of Th1 and Th17 cells into TGF-β1-secreting regulatory cells with low CD26 expression [76]. A number of short-term randomized controlled trials demonstrated that sitagliptin exerts anti-inflammatory properties in patients with T2D, resulting in increased expression of IL-10 (an anti-inflammatory cytokine) and reduced expression of various markers of low-grade inflammation, pro-inflammatory cytokines and cell adhesion molecules, such as C-reactive protein, IL-6, IL-18, TNF-α, serum amyloid A-low-density lipoprotein (SAA-LDL) complex, secreted phospholipase-A2 (sPLA2), soluble intercellular adhesion molecule-1 (sICAM-1) and E-selectin [77–79]. A recent Phase II clinical trial published in The New England Journal of Medicine showed that sitagliptin in combination with a standard immunosuppressive regimen of tacrolimus and sirolimus resulted in a low incidence of acute graft-versus-host disease by day 100 after myeloablative allogeneic hematopoietic stem-cell transplantation [80].

The anti-inflammatory and immunomodulatory properties of DPP-4i may therefore represent a further advantage in the prevention or management of cytokine storm in COVID-19. An alternative (but not mutually exclusive) explanation for the protective effects of DPP-4i against SARS-CoV-2 infection and progression relies on the hypothesis that pharmacological inhibition of DPP-4 may lead to a significant rise in circulating levels of the soluble form of DPP-4 (sDPP-4) [81], as it has been demonstrated in mice [82]. The subsequent relative abundance
of sDPP-4 could offer binding sites for SARS-CoV-2, thus preventing or limiting the attachment of the virus to the membrane-bound DPP-4 (mDPP-4) on target host cells, such as pneumocytes, endothelial cells or other cells relevant for viral spread and replication [81].

Proposed synergistic effects of vitamin D & DPP-4 inhibitors in COVID-19

Based on the aforementioned remarks, vitamin D and DPP-4i appear to exert synergistic anti-inflammatory and immunomodulatory effects that can be leveraged to ratchet down the virulence of SARS-CoV-2 and prevent the development and/or halt the progression of COVID-19-induced cytokine storm.

Our group [83–87] and other authors [88,89] previously showed that combination therapy with vitamin D and DPP-4i (VIDPP-4i) has the potential ability to protect beta-cell function in autoimmune diabetes. We also reported for the first time a remarkable clinical improvement after 3-year combination therapy with sitagliptin and vitamin D3 in a patient with mononeuritis multiplex, an unusual form of peripheral neuropathy characterized by the presence of perineuritis [90,91]. Recent in vitro and in vivo studies conducted in patients with T2D demonstrated that VIDPP-4i is able to: reduce the expression of pro-inflammatory cytokines (IFN-γ and IL-17); decrease the proliferation of CD4+ T cells and non-CD4+ cells; increase the levels of the anti-inflammatory cytokine IL-4; and upregulate the expression of IL-37 and FOXP3 (Forkhead box protein P3), which are well-known markers for regulatory T cells [92–94].

Furthermore, a study conducted in a rat model of fructose/salt-induced insulin resistance showed that the addition of vitamin D3 to the DPP-4i vildagliptin potentiated the renoprotective effects of vildagliptin, which consisted of a series of renal anti-inflammatory, antifibrotic, antioxidant and anti-apoptotic actions [95]. These findings may have additional clinical implications for COVID-19. In fact, chronic kidney disease has emerged as an independent risk factor for poor outcomes related to COVID-19 [1] and SARS-CoV-2 may cause kidney injury through direct cytopathic effects and indirect mechanisms secondary to the cytokine storm and the systemic involvement of the disease [96]. Overall, these findings suggest that vitamin D and DPP-4i administered together exert anti-inflammatory and immunomodulatory actions to a greater extent than vitamin D or DPP-4i administered alone. Moreover, VIDPP-4i may exert protective effects against endothelial dysfunction [97,98], which has been shown to play an important role in COVID-19 pathophysiology [10]. Figure 1 illustrates the potential protective effects of VIDPP-4i against SARS-CoV-2 infection and COVID-19 progression to the hyperinflammatory state and cytokine storm.

Conclusion

In conclusion, randomized controlled trials are warranted to determine whether VIDPP-4i represents an effective therapeutic intervention for prevention of COVID-19 progression to severe stages and modulation of the cytokine storm, which still represent unmet needs for reducing COVID-19-related hospitalization and mortality rates, particularly in vulnerable and high-risk populations such as diabetic patients.

Future perspective

Given its proven favorable safety profile (even when administered in high doses) [99], its inexpensive cost and ease of administration, vitamin D supplementation may be a simple therapeutic intervention to prevent disease progression and/or modulate the cytokine storm in COVID-19. On the other hand, DPP-4i exert anti-inflammatory, immunomodulatory and antifibrotic actions beyond their well-known role as glucose-lowering drugs for treatment of T2D. Importantly, DPP-4i are among the noninsulin glucose-lowering agents which have proven to be safe and effective (alone or in combination with insulin therapy) for management of T2D in the hospital [100,101] and outpatient settings [102], even in the context of COVID-19 [103]. This may facilitate the use of DPP-4i in hospitalized patients with COVID-19, without posing additional risks for serious adverse events, including hypoglycemia [102]. Accordingly, practical recommendations for the management of diabetes in patients with COVID-19 do not suggest discontinuation of DPP-4i [104]. A recent systematic review and meta-analysis of the Cardiovascular Outcomes Trials conducted by Grenet et al. [105] found that DPP-4i were not associated with either a decreased or an increased risk of overall (non-COVID-19) respiratory tract infection compared with placebo, thus supporting the practical recommendations for the management of diabetes during the COVID-19 pandemic. With this regard, the use of VIDPP-4i may offer a simple and safe means to hamper the hyperinflammatory state and cytokine storm in patients with COVID-19. In addition, the antihyperglycemic properties of DPP-4i, combined with the anti-inflammatory actions of such compounds reported in preclinical and clinical studies of endothelial...
Vitamin D & DPP-4 inhibitors for treatment of COVID-19  
Perspective

Expression of antimicrobial peptides (cathelicidin and defensin G69)
Differentiation and chemotactic/phagocytic capacity of monocytes/macrophages
Shift of macrophages towards M2 phenotype
Pro-inflammatory cytokines (IL-6, TNF-α)
Anti-inflammatory cytokines (IL-4, IL-37)
Th1 and Th17 cell differentiation, proliferation and activation
Macrophage and dendritic cell antigen-presentation and T-cell stimulatory ability
FOXP3 expression
Th2 cell differentiation and activation
Renin synthesis
SARS-CoV-2-mediated downregulation of ACE2
ACE2 expression and Ang (1–7) production
Ang II accumulation

Effects of DPP-4 on DPP-4/Ang II/ACE2 interaction [7]

Effects of DPP-4 on DPP-4/Ang II/ACE2 interaction [7]

Anti-inflammatory properties

Tolerogenic and immunomodulatory properties

Effects on RAS

Anti-infective properties

Anti-inflammatory, immunomodulatory and anti-fibrotic properties

Pleiotropic actions of DPP-4i

Figure 1. Potential protective effects of VIDPP-4i against SARS-CoV-2 infection and COVID-19 progression to the hyperinflammatory state and cytokine storm. The left side of the figure shows the protective effects of vitamin D, whereas the right side of the figure illustrates the protective effects of DPP-4 inhibitors (DPP-4i). Vitamin D and DPP-4i share many anti-inflammatory and immunomodulatory properties, resulting in synergistic actions of these compounds when they are co-administered. Vitamin D actions refer to those exerted by the biologically active form of vitamin D, which is also known as 1,25-dihydroxyvitamin D3 or calcitriol. ACE2: Angiotensin-converting enzyme 2; Ang (1–7): Angiotensin 1–7; Ang II: Angiotensin II; COVID-19: Coronavirus disease 2019; CRP: C-reactive protein; DPP-4i: DPP-4 inhibitors; FOXP3: Forkhead box protein P3; IFN-γ: Interferon-gamma; IL: Interleukin; M2: Alternatively activated macrophages; mDPP-4: Membrane-bound DPP-4; RAS: Renin-angiotensin system; SAA-LDL complex: Serum amyloid A-low-density lipoprotein complex; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; sDPP-4: Soluble form of DPP-4; sICAM-1: Soluble intercellular adhesion molecule-1; sPLA2: Secreted phospholipase-A2; TGF-β1: Transforming growth factor-beta 1; Th: T helper cell; TNF-α: Tumor necrosis factor-alpha; Treg: Regulatory T cell; VIDPP-4i: Vitamin D and DPP-4 inhibitor combination therapy.

dysfunction and atherosclerosis, make VIDPP-4i combinatorial approach an intriguing therapeutic strategy that may be particularly advantageous for patients at high risk for adverse outcomes related to COVID-19, especially for those with comorbid T2D and/or cardiovascular disease and atherosclerosis [106]. Nonetheless, DPP-4i have been investigated in numerous preclinical models of inflammatory diseases, such as arthritis, inflammatory bowel disease and multiple sclerosis [107]. Therefore, the wide repertoire of candidate DPP-4 substrates (e.g., cytokines, chemokines and neuropeptides) and the immunomodulatory actions of DPP-4i suggest that DPP-4i have a broad range of potential therapeutic applications. This may prompt the repurposing of DPP-4i as anti-inflammatory and immunomodulatory agents for the management of different inflammatory diseases, including COVID-19-induced cytokine storm [15,107].

Finally, vitamin D and DPP-4i may also play a role in the prevention of SARS-CoV-2 infection through mechanisms independent of their effects on innate and adaptive immunity. Indeed, vitamin D and DPP-4i might hamper different steps of the viral entry and viral infection cycle of SARS-CoV-2, specifically by interfering with RAS and ACE/Ang II/AT1R axis, and by counteracting the SARS-CoV-2-mediated downregulation of ACE2 expression as well as the interaction between DPP-4 and the receptor-binding S1 domain of the SARS-CoV-2 spike glycoprotein. However, these hypotheses need to be validated by robust mechanistic evidence.
**Executive summary**

**Coronavirus disease 2019-induced cytokine storm**
- A dysregulated immune response called ‘cytokine storm’ occurs in the most severe cases of coronavirus disease 2019 (COVID-19) and consists of an excessive production of pro-inflammatory cytokines.
- The cytokine storm can lead to acute respiratory distress syndrome, disseminated intravascular coagulation, multiorgan failure and ultimately death.
- Even though several repurposed drugs have been used for the treatment of COVID-19, only a few of them have been shown to offer a certain degree of effectiveness in preliminary intervention trials.

**Vitamin D & COVID-19**
- Vitamin D has been shown to exert anti-inflammatory and immunomodulatory properties, promoting antiviral effectors, reducing the expression of pro-inflammatory cytokines and inducing tolerogenic responses.
- Vitamin D has also been suggested to inhibit the synthesis of renin and to increase the expression of ACE2 and angiotensin 1–7 in the lung, thus preventing angiotensin II (Ang II) accumulation and reducing the Ang II pro-inflammatory activity.
- Observational studies found that a lower vitamin D status correlates with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity rates in the general population, along with higher levels of pro-inflammatory cytokines and worse prognosis in hospitalized patients with COVID-19.
- Preliminary findings from pilot intervention studies suggest that vitamin D administration may be effective in accelerating the viral clearance and reducing the disease severity in hospitalized patients with COVID-19.

**Dipeptidyl peptidase-4 inhibitors & COVID-19**
- Dipeptidyl peptidase-4 (DPP-4) has been suggested as a candidate binding target of the receptor-binding S1 domain of the SARS-CoV-2 spike glycoprotein.
- DPP-4 inhibitors (DPP-4i, a.k.a. gliptins) are a class of oral antihyperglycemic agents widely used for the treatment of Type 2 diabetes.
- DPP-4 inhibition may have the potential to interfere with the interaction between SARS-CoV-2 and target host cells.
- Emerging evidence suggests that DPP-4 inhibitors exhibit immunomodulatory, anti-inflammatory and antifibrotic properties beyond their well-established role as antihyperglycemic agents.
- Observational studies have recently showed that the use of DPP-4 inhibitors was associated with improved clinical outcomes in hospitalized patients with Type 2 diabetes and COVID-19.

**VIDPP-4i combination therapy & COVID-19**
- Based on emerging evidence coming from studies conducted in autoimmune diabetes, vitamin D and DPP-4 inhibitors appear to exert synergistic anti-inflammatory and immunomodulatory effects.
- According to the aforementioned remarks, vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) may represent a valid therapeutic approach to ratchet down the virulence of SARS-CoV-2, prevent disease progression and modulate the cytokine storm in COVID-19, particularly in patients at high risk for COVID-19-related adverse outcomes such as those with comorbid diabetes, cardiovascular disease and/or atherosclerosis.
- VIDPP-4i may also play a role in the prevention of SARS-CoV-2 infection by interfering with renin-angiotensin system and ACE/Ang II/AT1R axis, and countering the SARS-CoV-2-mediated downregulation of ACE2 as well as the interaction between DPP-4 and the SARS-CoV-2 spike glycoprotein.
- Randomized controlled trials are needed to establish whether VIDPP-4i represents a safe and effective intervention for prevention of SARS-CoV-2 infection and COVID-19 progression to the cytokine storm.

**Financial & competing interests disclosure**
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

**In memoriam**
This article is dedicated to the memory of Miriam Pinheiro, sister of Dr Marcelo Maia Pinheiro and frontline nurse who lost her life due to COVID-19 on 26 March 2021.

**References**
Papers of special note have been highlighted as: • of interest; •• of considerable interest

1. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. J. Community Health 45(6), 1270–1282 (2020).
2. Roy S, Mazumder T, Banik S. The association of cardiovascular diseases and diabetes mellitus with COVID-19 (SARS-CoV-2) and their possible mechanisms. SN. Compr. Clin. Med. 1–6 (2020) (Epub ahead of print).
Drucker DJ. Coronavirus infections and Type 2 diabetes-shared pathways with therapeutic implications. *Endocr. Rev.* 41(3), bnaa011 (2020).

- Provides significant insights into the shared pathophysiology underlying coronavirus disease 2019 (COVID-19) and Type 2 diabetes.

Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. *Immunity* 53(1), 19–25 (2020).

- Provides relevant information on the pathophysiology of COVID-19-related cytokine storm.

Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm: what we know so far. *Front. Immunol.* 11, 1446 (2020).

De Biasi S, Meschiari M, Gibellini L et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. *Nat. Commun.* 11(1), 3434 (2020).

Liu J, Li S, Liang B et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* 55, 102763 (2020).

Chen Z, John Wherry E. T cell responses in patients with COVID-19. *Nat. Rev. Immunol.* 20(9), 529–536 (2020).

Yang L, Liu S, Liu J et al. COVID-19 immunopathogenesis and immunotherapeutics. *Signal Transduct. Target. Ther.* 5(1), 128 (2020).

Jin Y, Ji W, Yang H, Chen X, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. *Signal Transduct. Target. Ther.* 5(1), 293 (2020).

Sinha P, Matthey MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? *JAMA Intern. Med.* 180(9), 1152–1154 (2020).

Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifirò G. Challenges for drug repurposing in the COVID-19 pandemic era. *Front. Pharmacol.* 11, 588654 (2020).

Lenze EJ, Mattar C, Zorumski CF et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. *JAMA* 324(22), 2292–2300 (2020).

Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. *Diabetes Care* 34(Suppl. 2), S276–S278 (2011).

Yazbeck R, Jaenisch SE, Abbott CA. Dipeptidyl peptidase 4 inhibitors: applications in innate immunity? *Biochem. Pharmacol.* 188, 114517 (2021) (Epub ahead of print).

Caprio M, Infante M, Calanchini M, Mammì C, Fabbri A. Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. *Eat. Weight Disord.* 22(1), 27–41 (2017).

Fabbri A, Infante M, Ricordi C. Editorial - vitamin D status: a key modulator of innate immunity and natural defense from acute viral respiratory infections. *Eur. Rev. Med. Pharmacol. Sci.* 24(7), 4048–4052 (2020).

Infante M, Ricordi C, Padilla N et al. The role of vitamin D and omega-3 PUFAs in islet transplantation. *Nutrients* 11(12), 2937 (2019).

Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. *Rev. Med. Virol.* 27(1), (2017).

Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. *Res. Endocr. Metab. Disord.* 18(2), 153–165 (2017).

Grant WB, Lahore H, McDonnell SL et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients* 12(4), 988 (2020).

Glinsky GV. Tripartite combination of candidate pandemic mitigation agents: vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells. *Biomedicines* 8(5), 129 (2020).

Bilezikian JP, Bikle D, Hewison M et al. Mechanisms in endocrinology: vitamin D and COVID-19. *Eur. J. Endocrinol.* 183(5), R133–R147 (2020).

Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. *J. Infect. Public Health* 13(10), 1373–1380 (2020).

Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of vitamin D status and other clinical characteristics with COVID-19 test results. *JAMA Netw. Open* 3(9), e2019722 (2020).

Merzon E, Tworowski D, Gorohovski A et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBs J.* 287(17), 3693–3702 (2020).

Whittimore PB. COVID-19 fatalities, latitude, sunlight, and vitamin D. *Am. J. Infect. Control* 48(9), 1042–1044 (2020).

Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? *Lancet Diabetes Endocrinol.* 8(9), 735–736 (2020).

Kara M, Ekn T, Ricci V, Kara Ö, Chang KV, Özçakar L. ‘Scientific strabismus’ or two related pandemics: coronavirus disease and vitamin D deficiency. *Br. J. Nutr.* 124(7), 736–741 (2020).

Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. *PLoS ONE* 15(9), e0239252 (2020).
31. Carugnano GE, Di Lecco V, Quaranta VN et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *J. Endocrinol. Invest.* 44(4), 765–771 (2020) (Epub ahead of print).

32. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. *Nutrients* 12(9), 2757 (2020).

33. De Smet D, De Smet K, Herroelen P, Grysspeerdt S, Martens GA. Serum 25(OH)D level on hospital admission associated with COVID-19 stage and mortality. *Am. J. Clin. Pathol.* 155(3), 381–388 (2020).

34. Hernández JL, Nan D, Fernandez-Ayala M et al. Vitamin D status in hospitalized patients with SARS-CoV-2 Infection. *J. Clin. Endocrinol. Metab.* (2020) (Epub ahead of print) https://doi.org/10.1210/clinem/dga733

35. Ye K, Tang F, Liao X et al. Does serum vitamin D level affect COVID-19 infection and its severity? A case-control study. *J. Am. Coll. Nutr.* 1–8 (2020) (Epub ahead of print).

36. Infante M, Buoso A, Pieri M et al. Low vitamin D status at admission as a risk factor for poor survival in hospitalized patients with COVID-19: an Italian retrospective study. *J. Am. Coll. Nutr.* 1–16 (2021) (Epub ahead of print).

37. Pereira M, Dantas Damascena A, Galvão Azevedo LM, de Almeida Oliveira T, da Mota Santana J. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. *Crit. Rev. Food Sci. Nutr.* 1–9 (2020) (Epub ahead of print).

38. French CB, McDonnell SL, Vieth R. 25-Hydroxyvitamin D variability within-person due to diurnal rhythm and illness: a case report. *J. Med. Case Rep.* 13(1), 29 (2019).

39. Smolders J, van den Ouweland J, Geven C, Pickkers P, Kox M. Letter to the Editor: vitamin D deficiency in COVID-19: mixing up cause and consequence. *Metabolism* 115, 154434 (2021).

40. Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. *Sci. Rep.* 10(1), 20191 (2020).

41. Jakovac H. COVID-19 and vitamin D—Is there a link and an opportunity for intervention? *Am. J. Physiol. Endocrinol. Metab.* 318(5), ES89 (2020).

42. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM et al. “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study”. *J. Steroid Biochem. Mol. Biol.* 203, 105751 (2020).

43. Malek Mahdavi A. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: implications for a potential treatment for COVID-19. *Rev. Med. Virol.* 30(5), e2119 (2020).

44. Rastogi A, Bhansali A, Khare N et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgrad. Med. J.* (2020) (Epub ahead of print) http://dx.doi.org/10.1136/postgradmedj-2020-139065

45. Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier JM, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients and its correlation with inflammatory markers. *Clin. Exp. Immunol.* 16(11), 1544 (2020).

46. Bourgonje AR, Abdulle AE, Timens W et al. Suggests the involvement of vitamin D deficiency in the hyperinflammatory state observed among patients with COVID-19. *Clin. Chim. Acta* 472, 70–74 (2020).

47. Malek Mahdavi A. Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID quasi-experimental study. *Nutrients* 12(11), 3577 (2020).

48. Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier JM, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: a quasi-experimental study. *J. Steroid Biochem. Mol. Biol.* 204, 105771 (2020).

49. Annweiler G, Corvaisier M, Gautier J et al. Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID quasi-experimental study. *Nutrients* 12(11), 154434 (2021).

50. Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier JM, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: a quasi-experimental study. *J. Steroid Biochem. Mol. Biol.* 204, 105771 (2020).

51. Bourgonje AR, Abdulle AE, Timens W et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study”. *J. Steroid Biochem. Mol. Biol.* 203, 105751 (2020).

52. Malek Mahdavi A. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: implications for a potential treatment for COVID-19. *Rev. Med. Virol.* 30(5), e2119 (2020).

53. Haniff TC, Harhay MO, Brown TS, Cohen JB, Mohardeh AM. Is there an association between COVID-19 mortality and the renin-angiotensin system? A call for epidemiologic investigations. *Clin. Infect. Dis.* 71(15), 870–874 (2020).

54. Aygun H. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. *Naunyn Schmiedeberg Arch. Pharmacol.* 393(7), 1157–1160 (2020).

55. Garvin MR, Alvarez C, Miller JI et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. *Elife* 9, e59177 (2020).

56. Khayat AS, de Assumpção PP, Meireles Khayat BC et al. ACE2 polymorphisms as potential players in COVID-19 outcome. *PLoS ONE* 15(12), e0243887 (2020).

57. Speeckaert MM, De Buyzere ML, Delanghe JR. Vitamin D binding protein polymorphism and COVID-19. *Clin. Chim. Acta* 572(1–2), 33–42 (2020).

58. Speeckaert MM, Speeckaert R, Delanghe JR. Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19. *Eur. Respir. J.* 2004638 (2021) (Epub ahead of print).

59. Speeckaert MM, De Buyzere ML, Delanghe JR. Vitamin D binding protein polymorphism and COVID-19. *J. Med. Virol.* 93(2), 705–707 (2021).

60. Klemann C, Wagner L, Stephan M, von Hösten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. *Clin. Exp. Immunol.* 185(1), 1–21 (2016).
Proteins associated with COVID-19 infection and progression: implications for diabetes therapy

56. Raj VS, Mou H, Smits SI et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* 495(7440), 251–254 (2013).

57. Maia Pinheiro M, Monteiro Pinheiro J, Moura Maia Pinheiro F. Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26? *CellR8* 4, e2835 (2020).

58. Li Y, Zhang Z, Yang L et al. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. *iScience* 23(6), 101160 (2020).

59. Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. *Emerg. Microbes Infect.* 9(1), 601–604 (2020).

60. Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. *Acta Diabetol.* 57(7), 779–783 (2020).

61. Chen CF, Chien CH, Yang YP et al. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19. *J. Clin. Med. Assoc.* 8(8), 710–711 (2020).

62. Basendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: a role for dipeptidyl peptidase 4 (DPP4) in disease severity? *J. Diabetes* 12(9), 649–658 (2020).

63. Strollo R, Pozzilli P. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19? *Diabetes Metab. Res. Rev.* 36(8), e3330 (2020).

**Provides insights into the potential mechanisms accounting for the role of DPP-4 inhibitors in the prevention of severe acute respiratory syndrome coronavirus 2 infection and/or progression of COVID-19. Also discusses the anti-inflammatory and antifibrotic properties exerted by these compounds.**

64. Soare A, Győrffy HA, Matei AE et al. Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis. *Arthritis Rheumatol.* 72(1), 137–149 (2020).

65. Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a role? *Diabetes Res. Clin. Pract.* 121, 10274–10278 (2020).

66. Pacheco R, Martinez-Navio JM, Lejeune M et al. Dipeptidyl peptidase-4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis. *Arthritis Rheumatol.* 72(1), 137–149 (2020).

67. Hatano R, Ohnuma K, Yamamoto J, Dang NH, Morimoto C. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). *J. Immunol.* 188(11), 5438–5447 (2012).

68. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). *J. Immunol.* 188(11), 5438–5447 (2012).

69. Chen YC, Chen TH, Sun CC et al. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in Type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study. *Acta Diabetol.* 57(10), 1181–1192 (2020).

70. Kawasaki T, Chen W, Htwe YM, Tatsumi K, Dudek SM. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 315(5), L834–L845 (2018).

71. Solerte SB, D’Addio F, Trevisan R et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with Type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. *Diabetes Care* 43(12), 2999–3006 (2020).

**Suggests a potential therapeutic role of DPP-4 inhibitors in hospitalized patients with COVID-19 and Type 2 diabetes.**

72. Mirani M, Favacchio G, Carrone F et al. Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with Type 2 diabetes and COVID-19: a case series from an academic hospital in Lombardy, Italy. *Diabetes Care* 43(12), 3042–3049 (2020).

**Suggests a potential therapeutic role of DPP-4 inhibitors in hospitalized patients with COVID-19 and Type 2 diabetes.**

73. Pal R, Banerjee M, Mukherjee S, Singh Bhogal R, Kaur A, Bhadada SK. Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. *Ther. Adv. Endocrinol. Metab.* 12, 20421882196482 (2021) (Epub ahead of print).

74. Aroor AR, Sowers JR, Jia G, DeMarco VG. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. *Am. J. Physiol. Heart Circ. Physiol.* 307(4), H477–H492 (2014).

75. Du H, Wang DW, Chen C. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients. *J. Cell. Mol. Med.* 24(18), 10274–10278 (2020).

76. Pinheiro MM, Stoppa CL, Valduga CJ et al. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro. *Eur. J. Pharmc. Sci.* 100, 17–24 (2017).

77. Makdisi A, Ghanim H, Vora M et al. Sitagliptin exerts an antiinflammatory action. *J. Clin. Endocrinol. Metab.* 97(9), 3333–3341 (2012).

78. Satoh-Asahara N, Sasaki Y, Wada H et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in Type 2 diabetic patients. *Metabolism* 62(3), 347–351 (2013).

79. Tremblay AJ, Lamarche B, Deacon CF, Weissagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. *Metabolism* 63(9), 1141–1148 (2014).
Perspective Pinheiro, Fabbri & Infante

80. Farag SS, Abu Zaid M, Schwartz JE et al. Dipeptidyl peptidase 4 inhibition for prophylaxis of acute graft-versus-host disease. N. Engl. J. Med. 384(1), 11–19 (2021).

81. Nauck MA, Meier JJ. Reduced COVID-19 mortality with sitagliptin treatment? Weighing the dissemination of potentially lifesaving findings against the assurance of high scientific standards. Diabetes Care 43(12), 2906–2909 (2020).

82. Varin EM, Mulvihill EE, Beaudry JL et al. Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition. Cell. Metab. 29(2), 320–334.e5 (2019).

83. Pinheiro MM, Pinheiro FM, Torres MA. Four-year clinical remission of Type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinol. Diabetes Metab. Case Rep. 2016, 16–0099 (2016).

84. Pinheiro MM, Pinheiro FMM, Trabachin ML. Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: an exploration to treat new-onset Type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future. Int. Immunopharmacol. 57, 11–17 (2018).

85. Pinheiro M, Pinheiro F. Prolonging the honeymoon phase in T1DM with sitagliptin plus vitamin D3. The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Madrid, Spain. Diabetes Technol. Ther. 22(S1), A1–A250 (2020).

86. Pinheiro MM, Pinheiro FMM, Diniz SN, Fabbri A, Infante M. Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes. Int. Immunopharmacol. 95, 107518 (2021).

87. Pinheiro MM, Pinheiro FMM, Trabachin ML. Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: an exploration to treat new-onset Type 1 diabetes mellitus and latent autoimmune diabetes in adults. Endocrinol. Diabetes Metab. Case Rep. 2016, 150136 (2016).

88. Rapti E, Karras S, Grammatiki M et al. Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults. Endocrinol. Diabetes Metab. Case Rep. 2016, 150136 (2016).

89. Zhang Z, Yan X, Wu C et al. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: a 1-year pilot study. Diabetes Metab. Res. Rev. 36(5), e3298 (2020).

90. Maia Pinheiro M, Moura Maia Pinheiro F, Pires Amaral Resende LL, Nogueira Diniz S, Fabbri A, Infante M. Improvement of pure sensory mononeuritis multiplex and IgG1 deficiency with sitagliptin plus Vitamin D3. Eur. Rev. Med. Pharmacol. Sci. 24(15), 8151–8159 (2020).

91. Maia Pinheiro M, Maia Pinheiro FM, Amaral Resende LLP, Diniz SN, Fabbri A, Infante M. 36-month follow-up of a pure sensory mononeuritis multiplex and IgG1 deficiency improved after sitagliptin and Vitamin D3. Eur. Rev. Med. Pharmacol. Sci. 25(4), 1768–1769 (2021).

92. Mahabadi-Ashiyani E, Sheikh V, Borzouei S, Salehi I, Alahgholi-Hajibehzad M. The increased T helper cells proliferation and inflammatory responses in patients with Type 2 diabetes mellitus is suppressed by sitagliptin and vitamin D3 in vitro. Inflamm. Res. 68(10), 857–866 (2019).

93. Telikani Z, Sheikh V, Zamani A et al. Effects of sitagliptin and vitamin D3 on T helper cell transcription factors and cytokine production in clinical subgroups of Type 2 diabetes mellitus: highlights upregulation of FOXP3 and IL-37. Immunopharmacol. Immunotoxicol. 41(2), 299–311 (2019).

94. Borzouei S, Sheikh V, Ghasemi M et al. Anti-Inflammatory effect of combined sitagliptin and vitamin D3 on cytokines profile in patients with Type 2 diabetes mellitus. J. Interferon Cytokine Res. 39(5), 293–301 (2019).

95. Wahba NS, Abdil-Ghany RH, Ghareib SA, Abdel-Aal M, Alsemeh AE. Vitamin D3 potentiates the renoprotective effects of vildagliptin induced by enzymatic DPP4 inhibition. Cell. Metab. 29(2), 320–334.e5 (2019).

96. Fortarezza F, Pezzuto F. COVID-19 nephropathy: what could pathologist say? Arch. Med. Sci. 8(1), 4–5 (2012).

97. Caprio M, Mammi C, Rosano GM. Vitamin D: a novel player in endothelial function and dysfunction. Arch. Med. Sci. 8(1), 4–5 (2012).

98. Aini K, Fukuda D, Tanaka K et al. Vildagliptin, a DPP-4 Inhibitor, attenuates endothelial dysfunction and atherogenesis in nondiabetic apolipoprotein E-deficient mice. Int. Heart J. 60(6), 1421–1429 (2019).

99. Fassio A, Adami G, Rossini M et al. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with Type 2 diabetes: a propensity score analysis from the CORONADO study. Diabetes Obes. Metab. (2021) (Epub ahead of print).

100. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes – 2021. Diabetes Care 44(Suppl. 1), S211–S220 (2021).

101. Lorenzo-González C, Atienza-Sánchez E, Reyes-Umpierrez D et al. Safety and efficacy of DPP4-inhibitors for management of hospitalized general medicine and surgery patients with Type 2 diabetes. Endocr. Pract. 26(7), 722–728 (2020) (Epub ahead of print).

102. Ling J, Cheng P, Ge L et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for Type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol. 56(5), 249–272 (2019).

103. Rousell R, Darmon P, Pichelin M et al. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with Type 2 diabetes: a propensity score analysis from the CORONADO study. Diabetes Obes. Metab. (2021) (Epub ahead of print).

104. Bornstein SR, Rubino F, Khunti K et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 8(6), 546–550 (2020).
105. Grenet G, Mekhaldi S, Mainbourg S et al. DPP-4 inhibitors and respiratory infection: a systematic review and meta-analysis of the cardiovascular outcomes trials. Diabetes Care 44(3), e36–e37 (2021).

106. de Almeida-Pititto B, Dualib PM, Zajdenverg L et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol. Metab. Syndr. 12, 75 (2020).

107. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol. Sci. 30(11), 600–607 (2009).